What is Biosense?
BIOSENSE specializes in a clinically validated breath ketone monitor designed to offer real-time biofeedback for tracking fat burn. This non-invasive device utilizes deep lung air sampling, presenting a pain-free alternative to traditional blood tests for ketone measurement. Endorsed by metabolic experts, BIOSENSE caters to health-conscious consumers aiming to optimize ketosis during fasting, achieve personalized metabolic goals, and enhance overall well-being. The company's technology is pivotal for individuals seeking to gain deeper insights into their metabolic state and fat-burning efficiency.
How much funding has Biosense raised?
Biosense has raised a total of $2.2M across 1 funding round:
Angel/Seed
$2.2M
Angel/Seed (2020): $2.2M with participation from iSelect Funds
Key Investors in Biosense
iSelect Funds
iSelect Funds is an early-stage investment firm that typically backs companies in the health and technology sectors. Their participation in Biosense's Angel/Seed round suggests a focus on innovative health monitoring solutions.
What's next for Biosense?
The recent major strategic investment positions Biosense for accelerated growth and market expansion. With a total funding base of $2.2M, the company is poised to enhance its product development, scale manufacturing, and broaden its market reach. This capital injection is expected to fuel further innovation in non-invasive metabolic monitoring, potentially solidifying Biosense's leadership in the burgeoning health-tech industry. The focus will likely be on leveraging its clinically validated technology to capture a larger share of the consumer health and wellness market.
See full Biosense company page
